IMPA1 polyclonal antibody

IMPA1, also known as Myo-inositol monophosphatase 1, is responsible for the procurement of inositol that is required for synthesis of phosphatidylinositol and polyphosphoinositides. IMPA1 exists as a homodimer and has been identified as the pharmacological target for lithium action in the brain. IMPA1 is the principal enzyme of the phosphatidyl inositol signaling pathway, and inhibition of inositol monophosphatase hydrolysis may underlie the anti-manic and anti-depressant actions of Li+. Studies indicate that a variation in the 277 codon coding region of the IMPA1 gene has not been observed in manic-depressive patients, therefore suggesting that polymorphisms or mutations in the noncoding regions of this gene may influence the lithium response in psychiatric patients.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .